Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval SummaryKatherine A. Thornton, Richard Pazdur, Shenghui Tang et al.|Clinical Cancer Research|2012Cited by 149
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast CancerGideon M. Blumenthal, Richard Pazdur, Nancy S. Scher et al.|Clinical Cancer Research|2013Cited by 120